Matching Placebo: Clinical Trials

424 trials of Matching Placebo, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

259 completed, 54 terminated, 36 recruiting, 22 not yet recruiting. 161 Phase 2, 115 Phase 1, 108 Phase 3, 39 Phase 4, 28 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 2161Completed 99, Terminated 24, Recruiting 11, Not yet recruiting 7, Unknown 7, Active not recruiting 5, Withdrawn 5, Enrolling by invitation 3
Phase 1115Completed 81, Terminated 15, Recruiting 7, Not yet recruiting 4, Unknown 3, Withdrawn 3, Active not recruiting 2
Phase 3108Completed 66, Terminated 16, Recruiting 10, Active not recruiting 7, Unknown 3, Withdrawn 3, Not yet recruiting 2, Enrolling by invitation 1
Phase 439Completed 22, Recruiting 4, Unknown 4, Active not recruiting 3, Terminated 3, Withdrawn 2, Not yet recruiting 1
Not applicable28Completed 11, Not yet recruiting 9, Recruiting 5, Unknown 2, Terminated 1
Early Phase 11Unknown 1

Follow Matching Placebo: new trials by email Literature Review of Matching Placebo trials Research Report on Matching Placebo

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 2 Trial of FT2109 for the Treatment of Psoriatic Arthritis
FT2109 Dosing Regimen 1, FT2109 Dosing Regimen 2, Matching Placebo - Psoriatic Arthritis (PsA)
Phase 2Not yet recruitingForward Therapeutics2102026-12-012026-10-09
HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide
Calcium-HMB Plus Vitamin D3, Matching placebo - Type 2 Diabetes Mellitus (T2DM), Sarcopenia
Phase 2Not yet recruitingVanderbilt University Medical Center902026-12-012026-08-28
Urolithin A and Its Effects on Attention and Sleep Timing in Healthcare Workers After Night Shifts
Urolithin A(StanYouth™️ Urolithin A), Matching Placebo - Attention, Sleep, and Circadian Rhythms After Night Shifts in Healthcare Workers
Not applicableNot yet recruitingLiangkai Chen402026-11-162026-11-19
Suzetrigine for Analgesiain Arthroscopic Rotator Cuff Repair
Suzetrigine (Journavx), Matching placebo, Standard multimodal analgesia - Artroscopic Surgery, Pain Management
Phase 4Not yet recruitingUniversity of Alabama at Birmingham1002026-11-012026-10-08
Tizanidine Premedication Versus Placebo for Laryngeal Mask Airway Insertion and Recovery in Adults Undergoing Ambulatory Surgery
Tizanidine, Placebo - Airway Management
Not applicableNot yet recruitingBeni-Suef University1102026-11-012026-11-06
Coronary MicrovAscular Diseases Intervention With Compound Danshen Dropping Pills
Compound Danshen Dripping Pills, Placebo - Coronary Microvascular Disease
Phase 4RecruitingQilu Hospital of Shandong University4962026-11-012026-11-18
Perioperative Mirogabalin for Pain Relief After Modified Radical Mastectomy
Mirogabalin, Placebo - Breast Cancer, Post Operative Pain
Not applicableNot yet recruitingCairo University502026-10-152026-10-19
Unflavored Powdered Multivitamin in Children
EllaOla Kids Essentials Unflavored Powdered Multivitamin, Placebo (Tapioca Fiber) - Selective Eating, Emotional Dysregulation
Not applicableNot yet recruitingEllaOla1662026-10-142026-10-13
Probiotic Trial for URTI Prevention in Healthy Adults
Probiotic Formula, Matching placebo - Upper Respiratory Tract Infections
Not applicableRecruitingHarokopio University1402026-10-012026-11-02
A Study of IBI3042 in Healthy Adult Participants
Investigational Drug: IBI3042, Matching Placebo - Healthy Volunteers (HV)
Phase 1Not yet recruitingFortvita Biologics (USA)Inc.322026-09-292026-09-25
Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis
Metformin, Matching Placebo - Idiopathic Pulmonary Fibrosis
Phase 3Not yet recruitingUniversity of Massachusetts, Worcester8002026-09-282026-09-08
A Phase 2 Study of MG-K10 in Chronic Spontaneous Urticaria
MG-K10 Injection, Matching Placebo - Chronic Urticaria, Idiopathic
Phase 2Not yet recruitingShanghai Mabgeek Biotech.Co.Ltd602026-09-232026-09-24
Evaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD)
611, Matching placebo - Dermatitis, Atopic
Phase 3RecruitingSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.2462026-09-222026-10-09
Phase 1b Clinical Study in Patients With Active Ulcerative Colitis
TP317, Matching placebo - Ulcerative Colitis (UC)
Phase 1Not yet recruitingThetis Pharmaceuticals LLC242026-09-162026-09-22
IBI3042 Study in Healthy Participants and Overweight or Obese Participants
Orforglipron, Matching Placebo, IBI3042 - Overweight, Healthy Participants
Phase 1RecruitingInnovent Biologics (Suzhou) Co. Ltd.1042026-09-072026-09-11
A Study of Probiotics in Patients With Acute Ischemic Stroke
probiotic supplement OMNi-BiOTiC® SR-9, Matching Placebo - Ischemic Stroke
Phase 2Not yet recruitingCapital Medical University2202026-09-012026-06-17
Safety and Efficacy of AV078 in Participants With Tuberous Sclerosis Complex (TSC) Refractory Epilepsy (RESTOR-1)
AV078, Placebo - Tuberous Sclerosis Complex, Epilepsy
Phase 2Not yet recruitingAeovian Pharmaceuticals, Inc.422026-09-012026-09-29
Safety of NRICM301 Added to Standard Care in Adults With Acute Ischemic Stroke
NRICM301, Matching Placebo - Acute Ischemic Stroke
Not applicableNot yet recruitingTri-Service General Hospital (TSGH)452026-09-012026-10-29
Single Ascending Dose Study of ACC085 Injection in Healthy Chinese Adults
Matching Placebo - Healthy Adult Participants
Phase 1RecruitingJiangsu Aidea Pharmaceutical Group Co., Ltd.472026-08-312026-09-25
The Therapeutic Effects of Ceylon Cinnamon Supplementation and a Self-Efficacy Educational Program on Glycemic Control, Lipid Profiles, and Pain in Type 2 Diabetes Mellitus With Painful Diabetic Peripheral Neuropathy
Ceylon Cinnamon (Cinnamomum verum) Supplement, Matching Placebo, Self-Efficacy-Based Educational Program - Type 2 Diabetes Mellitus, Painful Diabetic Peripheral Neuropathy (PDPN)
Not applicableNot yet recruitingJerash Private University9002026-08-012026-08-11

Showing 20 of 424. Sign in to see all of them.

Conditions studied

Asthma (13)  ·  Obesity (11)  ·  Pain (11)  ·  Amyotrophic Lateral Sclerosis (10)  ·  Diabetes Mellitus, Type 2 (10)  ·  Alzheimer Disease (9)  ·  Attention Deficit Disorder with Hyperactivity (8)  ·  COVID-19 (8)  ·  Cardiovascular Diseases (8)  ·  Dermatitis, Atopic (8)  ·  Migraine Disorders (7)  ·  Schizophrenia (7)  ·  Arthritis, Rheumatoid (6)  ·  Inflammation (6)  ·  Ischemic Stroke (6)

Sponsors

Regeneron Pharmaceuticals (24)  ·  Boehringer Ingelheim (9)  ·  Ironwood Pharmaceuticals, Inc. (9)  ·  Celldex Therapeutics (8)  ·  GlaxoSmithKline (8)  ·  Merit E. Cudkowicz, MD (8)  ·  AstraZeneca (7)  ·  Bayer (7)  ·  Mallinckrodt (7)  ·  Grünenthal GmbH (5)  ·  Merck Sharp & Dohme LLC (5)  ·  Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (5)  ·  Viatris Innovation GmbH (5)  ·  Cognition Therapeutics (4)  ·  Hoffmann-La Roche (4)

Countries

United States (234)  ·  Canada (63)  ·  Germany (60)  ·  United Kingdom (47)  ·  Poland (46)  ·  Spain (44)  ·  Australia (42)  ·  France (40)  ·  China (37)  ·  Netherlands (36)  ·  Italy (35)  ·  Belgium (29)  ·  Japan (23)  ·  Hungary (19)  ·  Israel (19)

Top investigators

Merit Cudkowicz, MD (6)  ·  Connie Celum, MD, MPH (3)  ·  Ivan Fan-ngai Hung (3)  ·  Adam Boxer, MD, PhD (2)  ·  Anne-Marie Wills, MD (2)

Results publications

PMID 11112243, PMID 16135345, PMID 17175134, PMID 18662331, PMID 19453963, PMID 20548058, PMID 22338037, PMID 22520687, PMID 23661689, PMID 25744676, PMID 26603732, PMID 27206567, PMID 27659698, PMID 27888609, PMID 28322750, PMID 29310498, PMID 33540241, PMID 33687069, PMID 34768178, PMID 35142535, PMID 39588375, PMID 40434633, PMID 40993471, PMID 42779129, PMID 18008230, PMID 18804555, PMID 18928378, PMID 19169140, PMID 19236277, PMID 19236279, PMID 19238149, PMID 19761871, PMID 19935017, PMID 19996872, PMID 20045700, PMID 20052461, PMID 20124229, PMID 20375406, PMID 20427778, PMID 20707784, PMID 20801122, PMID 20949623, PMID 21471141, PMID 21521847, PMID 21690488, PMID 21795446, PMID 21830967, PMID 22082672, PMID 22104981, PMID 22128201

NIH funding

2019 (13), 2017 (11), 2023 (8), 2016 (6), 2018 (4), 2008 (3), 2014 (3), 2025 (3), R01AG085029 (2), 2009 (1), 2015 (1), P30CA012197 (1), P30DK056350 (1), R01AG024154 (1), R01AG058660 (1)